Archive | October, 2010

RaynoLifeScience Portfolio: Earnings Update-ABAX,GPRO

Abaxis (ABAX) beat estimates with reported Q3 Revenues of $35.3M/$0.17 up 17% over last year’s comparable quarter. Cash position is $100.6M up from $87.6M last year’s Q3. March ’11 Fiscal Year estimates are $143M and $0.72/sh. Shares are up 0.97% today to $24 level up from low of $22.40 on Wednesday. GenProbe (GPRO) reported Q3 […]

Continue Reading 0

Trading Update:Exact Sciences (EXAS) Reports Positive Data for Colorectal Cancer Test

EXAS -Big Sell-Off on the News Exact Sciences (EXAS) was down 20% today after presenting its first validation data on the performance of its experimental, non-invasive colorectal cancer test. As of midday trading the stock was around $6.90 on huge volume over 5.5 M shares. The stock took off from $6.25 around Sep 22 and […]

Continue Reading 0

Great Day for Biotech Tools:Earnings Up ILMN,LIFE and PacBio (PACB) IPO

Timing is everything and Pacific Biosciences(PACB) took advantage of a good year for biotech stocks, better earnings for tools and Dx companies and a rebounding IPO market. Pacific Biosciences raised $200M($16) at the midpoint of the expected range and shares advanced to $16.25  with midday volume of over 4M shares. JPMorgan and Morgan Stanley led […]

Continue Reading 0

GE Buys Oncology Diagnostic Co. Clarient (CLRT)-Update- Dx Movers

GE announced the purchase of  Clarient (CLRT) for $5/share or $580M, a 34% premium over Clarient’s previous closing price. Revenues forecasted for 2011 and 2012 are at $114M and $136M respectively, pricing the deal at a Price to Sales of 4.25 to 5X. Revenues for Q1 were $26.6M with a loss of 370k; Q3 revenues […]

Continue Reading 0

Rayno Life Science Portfolio Big Movers: Gilead (GILD),Supergen (SUPG)

Risk is on today due to a weak dollar and that is usually good for Life Science stocks.MidCap biotechs are mainly green despite bad news from Amylin (AMLN) $11.35 down 44%, and partner Alkermes (ALKS) $10.91 down 24.75% a setback on their long- acting drug for diabetes called Bydureon which will require additional clinical trials.The FDA […]

Continue Reading 0

Rayno Life Science Portfolio Notes- Q3 Earnings in Two weeks

The Rayno Life Science Portfolio is up 20% and later this month we will see important earnings reports from tools and diagnostics companies. Life Science stocks are outperforming the NASDAQ and S&P in 2010. Exact Sciences(EXAS) $8.89 was a high flier for Q3 with the stock tripling from the $3 level. Pre-clinical validation data on […]

Continue Reading 0

IMMUCOR(BLUD) Cuts Guidance,Economy and Blood Demand Cited-Update 1

Stock is down over 18% at 3p near $16.5 on 7M shares A “Pure Play “Immunohematology Diagnostic Company Immucor announced Fiscal Q1 2011 results yesterday with a revenue shortfall of  (9%) on traditional reagents $49.621M vs $54.719M in Fiscal 2010. Total Consolidated Revenues were $83.6M, 1% above the same period last year. Gross margin was […]

Continue Reading 0

Rayno Life Science Portfolio: Update Tools and Dx

2010 Original Price % Ret. P Price % Recomm 3/29/10 Q2 12/1/10 Ret. Abaxis ABAX 2/2/09 15 79 21.2 27.86 85 CardioV.Sys. CSII 11/5/10 7.15 8.65 21 Celera CRA 3/28/10 7 6.49 5.66 -19 GenProbe GPRO 2/2/09 45 7 46.3 52.77 17 Illumina ILMN 2/2/09 29 35 43.1 61.79 113 Immucor BLUD 4/5/10 20 18.6 […]

Continue Reading 0

2010 Rayno Life Science Portfolio: Update Biopharma

2010 Price Original P Price % Ret 7/2/10 Recomm 12/1/10 Alexion ALXN 50.45 2/2/09 35 76.24 117 Ardea Biosci RDEA 19.5 2/2/09 12 22.26 85 Amgen AMGN 51.7 2/2/09 55 53.52 -5 Biogen BIIB 49.42 2/2/09 49 65.37 33 Cephalon CEPH 55.95 2/2/09 77 64.26 -16.5 Cubist CBST 20.7 2/2/09 22 20.98 -4.5 Exelixis EXEL […]

Continue Reading 0